Nasdaq · CIK 0001130598
TRAW Traws Pharma, Inc.
Insider trading from SEC Form 4. Last filing Jul 16, 2026. Close $0.42 on Oct 12, 2026, 0% from the 52-week low and -86% from the high.
In brief
Traws Pharma, Inc. (TRAW) has 48 SEC Form 4 filings on file from 11 insiders, the latest filed on Jul 16, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
1 open-market trade has been scored at TRAW. The newest: Orbimed Advisors LLC (10% owner) bought $998k of stock on Apr 16, 2026, filed Apr 28, 2026, scored 37 (weak).
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Traws Pharma, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 37Weak | Orbimed Advisors LLC owner buy | $998k 597,729 shares | +99% | - |
Transactions
The newest 50 of 65 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 9, 2026 | Charles David Pauza Chief Science Officer Virology | AGrant or award Stock Option (right to buy)derivative | +97,000 | $0.00 | $0 | 97,000 | Jul 16, 2026 |
| Jul 9, 2026 | Nikolay Savchuk Chief Operating Officer | AGrant or award Stock Option (right to buy)derivative | +93,000 | $0.00 | $0 | 93,000 | Jul 15, 2026 |
| Jul 9, 2026 | Werner Cautreels Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +14,150 | $0.00 | $0 | 14,150 | Jul 15, 2026 |
| Jul 9, 2026 | Iain D. Dukes Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +274,000 | $0.00 | $0 | 274,000 | Jul 14, 2026 |
| Jul 9, 2026 | John Harold Leaman director | AGrant or award Stock Option (right to buy)derivative | +14,150 | $0.00 | $0 | 14,150 | Jul 14, 2026 |
| Jul 9, 2026 | Mary Teresa Shoemaker director | AGrant or award Stock Option (right to buy)derivative | +14,150 | $0.00 | $0 | 14,150 | Jul 14, 2026 |
| Jul 9, 2026 | Trafford Clarke director | AGrant or award Stock Option (right to buy)derivative | +14,150 | $0.00 | $0 | 14,150 | Jul 14, 2026 |
| Jul 9, 2026 | Charles Nolan Parker Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +90,000 | $0.00 | $0 | 90,000 | Jul 14, 2026 |
| Jul 9, 2026 | Jack E Stover director | AGrant or award Stock Option (right to buy)derivative | +14,150 | $0.00 | $0 | 14,150 | Jul 14, 2026 |
| Jul 9, 2026 | Robert Redfield Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +84,000 | $0.00 | $0 | 84,000 | Jul 14, 2026 |
| Apr 16, 2026 | Orbimed Advisors LLC owner | POpen-market purchase Common Stockindirect: See Footnote | +597,729 | $1.67 | $998k | 1,203,250 | Apr 28, 2026 |
| Apr 16, 2026 | Orbimed Advisors LLC owner | POpen-market purchase Series A Warrants (right to buy)derivativeindirect: See Footnote | +597,729 | - | - | 597,729 | Apr 28, 2026 |
| Apr 16, 2026 | Orbimed Advisors LLC owner | POpen-market purchase Series B Warrants (right to buy)derivativeindirect: See Footnote | +597,729 | - | - | 597,729 | Apr 28, 2026 |
| Apr 16, 2026 | Orbimed Advisors LLC owner | POpen-market purchase Series C Warrants (right to buy)derivativeindirect: See Footnote | +1,793,187 | - | - | 1,793,187 | Apr 28, 2026 |
| Dec 12, 2025 | Charles Nolan Parker Chief Financial Officer | AGrant or award Common Stock | +15,393 | $0.00 | $0 | 15,393 | Apr 8, 2026 |
| Oct 12, 2025 | Charles Nolan Parker Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +32,406 | $0.00 | $0 | 32,406 | Apr 8, 2026 |
| Dec 12, 2025 | Charles Nolan Parker Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +61,571 | $0.00 | $0 | 61,571 | Apr 8, 2026 |
| Mar 8, 2026 | Charles Nolan Parker Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +104,544 | $0.00 | $0 | 104,544 | Apr 8, 2026 |
| Mar 8, 2026 | Trafford Clarke director | AGrant or award Stock Option (right to buy)derivative | +33,435 | $0.00 | $0 | 33,435 | Mar 10, 2026 |
| Mar 8, 2026 | Iain D. Dukes Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +231,336 | $0.00 | $0 | 231,336 | Mar 10, 2026 |
| Mar 8, 2026 | John Harold Leaman director | AGrant or award Stock Option (right to buy)derivative | +33,435 | $0.00 | $0 | 33,435 | Mar 10, 2026 |
| Mar 8, 2026 | Charles David Pauza Chief Science Officer Virology | AGrant or award Stock Option (right to buy)derivative | +118,367 | $0.00 | $0 | 118,367 | Mar 10, 2026 |
| Mar 8, 2026 | Robert Redfield Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +108,854 | $0.00 | $0 | 108,854 | Mar 10, 2026 |
| Mar 8, 2026 | Jack E Stover director | AGrant or award Stock Option (right to buy)derivative | +33,435 | $0.00 | $0 | 33,435 | Mar 10, 2026 |
| Mar 8, 2026 | Nikolay Savchuk Chief Operating Officer | AGrant or award Stock Option (right to buy)derivative | +96,899 | $0.00 | $0 | 96,899 | Mar 10, 2026 |
| Mar 8, 2026 | Mary Teresa Shoemaker director | AGrant or award Stock Option (right to buy)derivative | +33,435 | $0.00 | $0 | 33,435 | Mar 10, 2026 |
| Mar 8, 2026 | Werner Cautreels Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +31,258 | $0.00 | $0 | 31,258 | Mar 10, 2026 |
| Dec 12, 2025 | Charles David Pauza Chief Science Officer Virology | AGrant or award Common Stock | +18,471 | $0.00 | $0 | 115,971 | Dec 16, 2025 |
| Dec 12, 2025 | Robert Redfield Chief Medical Officer | AGrant or award Common Stock | +16,419 | $0.00 | $0 | 113,919 | Dec 16, 2025 |
| Dec 12, 2025 | Jack E Stover director | AGrant or award Common Stock | +6,157 | $0.00 | $0 | 6,165 | Dec 16, 2025 |
| Dec 12, 2025 | Nikolay Savchuk Chief Operating Officer | AGrant or award Common Stock | +16,419 | $0.00 | $0 | 150,606 | Dec 16, 2025 |
| Dec 12, 2025 | Mary Teresa Shoemaker director | AGrant or award Common Stock | +6,157 | $0.00 | $0 | 6,292 | Dec 16, 2025 |
| Dec 12, 2025 | Werner Cautreels Chief Executive Officer | AGrant or award Common Stock | +4,874 | $0.00 | $0 | 109,222 | Dec 16, 2025 |
| Dec 12, 2025 | Trafford Clarke director | AGrant or award Common Stock | +6,157 | $0.00 | $0 | 6,157 | Dec 16, 2025 |
| Dec 12, 2025 | Iain D. Dukes Chief Executive Officer | AGrant or award Common Stock | +36,943 | $0.00 | $0 | 171,130 | Dec 16, 2025 |
| Dec 12, 2025 | John Harold Leaman director | AGrant or award Common Stock | +4,058 | $0.00 | $0 | 4,058 | Dec 16, 2025 |
| Dec 12, 2025 | John Harold Leaman director | AGrant or award Stock Option (right to purchase)derivative | +16,234 | $0.00 | $0 | 16,234 | Dec 16, 2025 |
| Dec 12, 2025 | Charles David Pauza Chief Science Officer Virology | AGrant or award Stock Option (right to purchase)derivative | +73,886 | $0.00 | $0 | 73,886 | Dec 16, 2025 |
| Dec 12, 2025 | Robert Redfield Chief Medical Officer | AGrant or award Stock Option (right to purchase)derivative | +65,676 | $0.00 | $0 | 65,676 | Dec 16, 2025 |
| Dec 12, 2025 | Jack E Stover director | AGrant or award Stock Option (right to purchase)derivative | +24,629 | $0.00 | $0 | 24,629 | Dec 16, 2025 |
| Dec 12, 2025 | Nikolay Savchuk Chief Operating Officer | AGrant or award Stock Option (right to purchase)derivative | +65,676 | $0.00 | $0 | 65,676 | Dec 16, 2025 |
| Dec 12, 2025 | Mary Teresa Shoemaker director | AGrant or award Stock Option (right to purchase)derivative | +24,629 | $0.00 | $0 | 24,629 | Dec 16, 2025 |
| Dec 12, 2025 | Werner Cautreels Chief Executive Officer | AGrant or award Stock Option (right to purchase)derivative | +19,496 | $0.00 | $0 | 19,496 | Dec 16, 2025 |
| Dec 12, 2025 | Trafford Clarke director | AGrant or award Stock Option (right to purchase)derivative | +24,629 | $0.00 | $0 | 24,629 | Dec 16, 2025 |
| Dec 12, 2025 | Iain D. Dukes Chief Executive Officer | AGrant or award Stock Option (right to purchase)derivative | +147,771 | $0.00 | $0 | 147,771 | Dec 16, 2025 |
| Nov 21, 2025 | John Harold Leaman director | AGrant or award Stock Option (right to purchase)derivative | +12,770 | $0.00 | $0 | 12,770 | Nov 25, 2025 |
| Oct 12, 2025 | Werner Cautreels Chief Executive Officer | AGrant or award Stock Option (right to purchase)derivative | +11,530 | $0.00 | $0 | 11,530 | Oct 15, 2025 |
| Oct 12, 2025 | Trafford Clarke director | AGrant or award Stock Option (right to purchase)derivative | +11,530 | $0.00 | $0 | 11,530 | Oct 15, 2025 |
| Oct 12, 2025 | Iain D. Dukes Chief Executive Officer | AGrant or award Stock Option (right to purchase)derivative | +64,839 | $0.00 | $0 | 64,839 | Oct 15, 2025 |
| Oct 12, 2025 | Charles David Pauza Chief Science Officer Virology | AGrant or award Stock Option (right to purchase)derivative | +32,406 | $0.00 | $0 | 32,406 | Oct 15, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Werner CautreelsChief Executive Officer
- Trafford Clarkedirector
- Iain D. DukesChief Executive Officer
- John Harold Leamandirector
- Orbimed Advisors LLCdirector, owner
- Charles Nolan ParkerChief Financial Officer
- Charles David PauzaChief Science Officer Virology
- Robert RedfieldChief Medical Officer
- Jack E Stoverceo, officer, director
- Nikolay SavchukChief Operating Officer
- Mary Teresa Shoemakerdirector
Questions about TRAW
Answered from the filings on this page, as of the latest one.
Are insiders buying TRAW?
No. In the last 90 days no insider at Traws Pharma, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade TRAW on the open market?
Orbimed Advisors LLC (10% owner) bought $998k of TRAW on Apr 16, 2026 and filed the Form 4 on Apr 28, 2026. InsiderTell scored 37 (weak).
How many insiders file Form 4 at Traws Pharma, Inc.?
11 people have filed a Form 4 at Traws Pharma, Inc., among them Werner Cautreels (Chief Executive Officer), Trafford Clarke (director), Iain D. Dukes (Chief Executive Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.